Gabor Tigyi

A two-step approach to qPCR experimental design and software for data analysis

Huazhang Guo, Larry Tague, Ramesh Ray, 2010, BMC Bioinformatics.

Lysophosphatidic acid (LPA)‐induced vasodilator‐stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC‐3 prostate cancer cells

Gordon B Mills, Gabor Tigyi, G. Mills, 2008, Molecular oncology.

Different Residues Mediate Recognition of 1-O-Oleyllysophosphatidic Acid and Rosiglitazone in the Ligand Binding Domain of Peroxisome Proliferator-activated Receptor γ*

Satoshi Yasuda, Hongbin Yuan, Daniel L Baker, 2006, Journal of Biological Chemistry.

Plasma lysophosphatidic acid concentration and ovarian cancer.

Daniel L Baker, Gabor Tigyi, D. Baker, 2002, JAMA.

The FASEB Journal express article 10.1096/fj.05-4810fje. Published online November 30, 2005. ©2005 FASEB

Gabor Tigyi, Y. Fujiwara, V. Natarajan, 2022 .

Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression

Gabor Tigyi, Y. Fujiwara, R. Pelanda, 2013, Cancer Immunology Research.

International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature

Kevin R. Lynch, Gabor Tigyi, J. Chun, 2002, Pharmacological Reviews.

Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha.

Feng Hao, Duane D. Miller, Gabor Tigyi, 2007, Biochimica et biophysica acta.